Hypothyroidism

Eisai and Merck & Co., Inc. Present Results from Phase 3 LEAP-002 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

Retrieved on: 
월요일, 9월 12, 2022
MSD, Adult, Proteinuria, OS, Clinical research, RCC, Safety, IV, Stomach, CI, Diarrhea, Colorectal cancer, Merck & Co., Hypothyroidism, European Society for Medical Oncology, Senior, Pembrolizumab, Melanoma, Hypertension, Survival, Patient, HCC, Physician, LEAP, Eisai, Acral lentiginous melanoma, ORR, Oncology, Progression-free survival, Head, Sorafenib, Renal cell carcinoma, Research, Cancer, Large-cell lung carcinoma, Henry "Trae" Winter, Congress, Union, PFS, Esophageal cancer, Merck, PPE, RECIST, Hepatocellular carcinoma, Toxicity, ESMO, Pharmaceutical industry, EU

The median OS was 21.2 months (95% CI: 19.0-23.6) for LENVIMA plus KEYTRUDA and 19.0 months (95% CI: 17.2-21.7) for LENVIMA monotherapy.

Key Points: 
  • The median OS was 21.2 months (95% CI: 19.0-23.6) for LENVIMA plus KEYTRUDA and 19.0 months (95% CI: 17.2-21.7) for LENVIMA monotherapy.
  • LEAP-002 is a multicenter, randomized, double-blinded, active-controlled Phase 3 trial (ClinicalTrials.gov, NCT03713593(New Window)) evaluating LENVIMA plus KEYTRUDA versus LENVIMA monotherapy for the first-line treatment of adult patients with uHCC.
  • Grade 5 TRAEs occurred in 1.0% of patients treated with LENVIMA plus KEYTRUDA versus 0.8% of patients treated with LENVIMA monotherapy.
  • Post-study systematic anti-cancer treatments were given for 44.1% of patients receiving LENVIMA plus KEYTRUDA versus 52.1% of those receiving LENVIMA monotherapy.

Springboard Enterprises Announces their 2022 Digital Health Innovation Cohort Companies

Retrieved on: 
목요일, 9월 8, 2022
Technology, Women, Other Technology, Health Technology, Software, Internet, Health, Consumer, General Health, Hashimoto's thyroiditis, Genome, Endometriosis, Cheek, Technology, Food, Program, Telehealth, Allergy, Insurance, Ageing, Pregnancy, Parent, Blood, Springboard, Health, Asthma, Quality of life, Miscarriage, Cohort, Menopause, Dermatitis, Antibody, COPD, Boot, Automotive Supplier Innovation Program, Infertility, Woman, Hypothyroidism, Growth, Initial public offering, Patient, Management, Health insurance, Medical imaging

Celebrating more than 20 years of supporting women-led companies and industry transformation, Springboard Enterprises has announced its 2022 Innovation Program: Digital Health Cohort.

Key Points: 
  • Celebrating more than 20 years of supporting women-led companies and industry transformation, Springboard Enterprises has announced its 2022 Innovation Program: Digital Health Cohort.
  • For over two decades, Springboard Enterprises has accelerated the growth of entrepreneurial companies founded and led by women and the 2022 cohort is an example of this mission.
  • The women in this cohort are part of the digital health revolution driving innovations in patient-focused care and will ultimately contribute to people worldwide achieving a higher standard of wellness, said Springboard Enterprises CEO, Natalie Buford-Young.
  • Springboards Digital Health Innovation Cohortis a program for women-led digital health companies seeking growth-funding along with connections to experts and strategic partners for product development and expansion.

EMD Serono to Highlight Data at ESMO 2022 with Potential for Transformative Impact on Cancer Patients

Retrieved on: 
수요일, 9월 7, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Fatigue, UC, Hepatotoxicity, Liver, Pfizer, Pleural effusion, Thyroiditis, Grade 3, Maintenance, Hypothyroidism, TEN, Breathe Me, PD-1, Grade 2, Photophobia, Pulmonary embolism, PD-L1, Nausea, Patient, Avelumab, Field line, Stevens–Johnson syndrome, Incidence, Eosinophilia, Pneumonitis, Headache, Insulin, FDA, Diabetes, Hyperthyroidism, Creatinine, Diarrhea, Hyperglycemia, Kidney, Erythroderma, Pneumonia, AST, Hepatitis, Colitis, Rash, Hypophysitis, MCC, Lists of diseases, Fourth grade, Endocrinology, Hypopituitarism, Dermatitis, Degenerative disease, Prednisone, Neoplasm, HIV disease progression rates, RCC, DRESS, Brain Quest Grades 3 & 4, SJS, Infection, ALT, Edema, Merck Group, Drug, Adrenal insufficiency, Diabetic ketoacidosis, Vaccine, Pharmaceutical industry, Cytomegalovirus, Angela Merkel

Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroid therapy.

Key Points: 
  • Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroid therapy.
  • Immune-mediated pneumonitis occurred in 1.2% (21/1738) of patients, including fatal (0.1%), Grade 4 (0.1%), Grade 3 (0.3%) and Grade 2 (0.6%) adverse reactions.
  • Immune-mediated colitis occurred in 1.5% (26/1738) of patients, including Grade 3 (0.4%) and Grade 2 (0.7%) adverse reactions.
  • Immune-mediated adrenal insufficiency occurred in 0.5% (8/1738) of patients, including Grade 3 (0.1%) and Grade 2 (0.3%) adverse reactions.

Sernova Receives Second Tranche Equity Investment from Evotec of $6.8 Million at a Price of $2.50 Per Share

Retrieved on: 
목요일, 9월 1, 2022
University, Conditional sentence, Haemophilia, CEO, Technology, Cell, Survival, Potency (pharmacology), IPSC, NASDAQ, Protein, Exercise, Regenerative medicine, Type 1 diabetes, EVO, Degenerative disease, FSE, TSX, Indian stock exchange, GLOBE, VIII, Company, Therapy, Immune system, PSH, Diabetes, Thyroid disease, Hypothyroidism, Chicago (franchise), Evotec, Trial of the century, Patient, Thyroid, Pharmaceutical industry

Upon completion of the second tranche, Evotecs strategic investment in Sernova totals $27,098,000.

Key Points: 
  • Upon completion of the second tranche, Evotecs strategic investment in Sernova totals $27,098,000.
  • Evotecs investment at $2.50 per share, significantly more than double yesterdays closing price, reflects the value our strategic partner places on Sernova relative to the current trading price on the TSX, commented Dr. Philip Toleikis, President and CEO of Sernova Corp.
  • The dedication and synergy of our mutual teams to advance the iPSC diabetes program expeditiously has been impressive.
  • In May 2022, Sernova and Evotec entered into a global strategic collaboration to develop an implantable off-the-shelf iPSC-based (induced pluripotent stem cells) beta cell replacement therapy.

Professional Golfer Aza Muñoz Returns to LPGA Tour with New Solution for Treating Her Hypothyroidism

Retrieved on: 
수요일, 8월 24, 2022
Sports, General Sports, Alternative Medicine, Managed Care, Other Health, Health, Seniors, Pharmaceutical, Golf, Hispanic, Consumer, Muscle weakness, Insurance, Rash, Thyroiditis, Myocardial infarction, Breathe Me, Absorption, Irritability, Glycerol, Risk, Hypothyroidism, Levothyroxine, Patient, Diabetes, Cardiovascular disease, Menstruation, Obesity, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Appetite, Food, Hashimoto's thyroiditis, Headache, Insomnia, Heat intolerance, Tremor, Weight gain, FDA, Weight loss, THE, Social media, Partnership, Tablet, Spasm, Diarrhea, Stiff-person syndrome, Lists of diseases, Thyroid hormones, Pharmacy, Nervous, Diet, Multimedia, Water, Plasma protein binding, Â, Aza, LPGA, Health, Atrial fibrillation, IBSA, Hyperthyroidism, LPGA Tour Championship, Golf, McMillan, Arrhythmia, Diagnosis, CONTROL, Excipient, Common, Lethargy, Adrenal insufficiency, Public relations, Pharmaceutical industry, Meat

Professional golfer Azahara (Aza) Muoz will return to the LPGA Tour this fall as a new mom and as the new spokesperson for Tirosint-SOL (levothyroxine sodium) solution .

Key Points: 
  • Professional golfer Azahara (Aza) Muoz will return to the LPGA Tour this fall as a new mom and as the new spokesperson for Tirosint-SOL (levothyroxine sodium) solution .
  • My body ached, and practicing golf was so tough because I was always tired, said Muoz.
  • She tried to treat her condition using conventional thyroid medicine, but she still struggled with the symptoms of hypothyroidism.
  • We wish Aza the best of luck and health as she returns to the Tour!

BioInnovation Institute announces new Venture House program and initial intake of four innovative companies

Retrieved on: 
화요일, 8월 23, 2022
Patient, Chronic liver disease, Food, Technology, Human, Program, Research, Charisma House, Novo Nordisk Foundation, Artificial intelligence, Liver, Therapy, Innovation, Solution, Stoma, House, EUR, Acceleration, Microtechnology, BII, Company, English brewery cask units, Hypothyroidism, Taste, Growth, Pharmaceutical industry, Insurance, Fine chemical

COPENHAGEN, Denmark, Aug. 23, 2022 /PRNewswire/ -- BioInnovation Institute (BII), an international commercial foundation with a non-profit objective incubating and accelerating world-class life science research, today announces that four companies have joined its new Venture House program.

Key Points: 
  • Venture House replaces the BII's former Creation House program to support Venture Lab Companies with further financing to accelerate growth.
  • COPENHAGEN, Denmark, Aug. 23, 2022 /PRNewswire/ -- BioInnovation Institute (BII), an international commercial foundation with a non-profit objective incubating and accelerating world-class life science research, today announces that four companies have joined its new Venture House program.
  • Formerly known as Creation House, the new Venture House program consists of the same 18-month long program with a risk-free convertible loan of EUR 1.3M.
  • Bobby Soni, Chief Business Officer, at BioInnovation Institute,said: "We are thrilled to present our new Venture House program.

BioInnovation Institute announces new Venture House program and initial intake of four innovative companies

Retrieved on: 
화요일, 8월 23, 2022
Patient, Chronic liver disease, Food, Technology, Human, Program, Research, Charisma House, Novo Nordisk Foundation, Artificial intelligence, Liver, Therapy, Innovation, Solution, Stoma, House, EUR, Acceleration, Microtechnology, BII, Company, English brewery cask units, Hypothyroidism, Taste, Growth, Pharmaceutical industry, Insurance, Fine chemical

COPENHAGEN, Denmark, Aug. 23, 2022 /PRNewswire/ -- BioInnovation Institute (BII), an international commercial foundation with a non-profit objective incubating and accelerating world-class life science research, today announces that four companies have joined its new Venture House program.

Key Points: 
  • Venture House replaces the BII's former Creation House program to support Venture Lab Companies with further financing to accelerate growth.
  • COPENHAGEN, Denmark, Aug. 23, 2022 /PRNewswire/ -- BioInnovation Institute (BII), an international commercial foundation with a non-profit objective incubating and accelerating world-class life science research, today announces that four companies have joined its new Venture House program.
  • Formerly known as Creation House, the new Venture House program consists of the same 18-month long program with a risk-free convertible loan of EUR 1.3M.
  • Bobby Soni, Chief Business Officer, at BioInnovation Institute,said: "We are thrilled to present our new Venture House program.

Global Metabolic Partnering Report 2022: Deal Trends, Players and Financials Analysis of 1100+ Deals Signed Since 2015 - ResearchAndMarkets.com

Retrieved on: 
목요일, 8월 18, 2022
Health, Pharmaceutical, Nutrition, Hypothyroidism, Addison's disease, Fatty liver disease, Non-alcoholic fatty liver disease, Vitamin, Liver disease, Directory, Technology, Metabolism, Diabetes insipidus, SEC, Cushing's syndrome, Chapter Four, Chapter Five, Chapter Three, Lysosomal storage disease, Diabetes, Review, NASH, Contract, Syndrome of inappropriate antidiuretic hormone secretion, Syndrome, Biotechnology, Metabolic disorder, Chapter Six, Thyroid disease, SIADH, Chapter One, Chapter Two, Gallstone, Rickets, Hyperlink, Collection, Acromegaly, Orientation, Cirrhosis, A-Z, Pharmaceutical industry, Risk management, Pheochromocytoma, Hypercalcaemia, Hypogonadism, Hypocalcemia, Hyperaldosteronism, Phenylketonuria, Hypopituitarism, Hyperthyroidism

Global Metabolic Partnering 2015 to 2022 provides the full collection of 1100+ Metabolic disease deals signed between the world's pharmaceutical and biotechnology companies since 2015.

Key Points: 
  • Global Metabolic Partnering 2015 to 2022 provides the full collection of 1100+ Metabolic disease deals signed between the world's pharmaceutical and biotechnology companies since 2015.
  • The report takes readers through the comprehensive Metabolic disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Metabolic deals.
  • In addition, a comprehensive appendix is provided with each report of all Metabolic partnering deals signed and announced since 2015.
  • Global Metabolic Partnering 2015 to 2022 includes:
    In Global Metabolic Partnering 2015 to 2022, available deals and contracts are listed by:

AvoMD Enters into Content Licensing Agreement with the American Academy of Family Physicians

Retrieved on: 
목요일, 7월 28, 2022
Algorithm, Time, Health care, American Academy, AFP, Physician, CEO, Partnership, American Academy of Family Physicians, Electronic health record, Hypothyroidism, American Family Physician, Technology, EHR, AAFP, Patient, American Family, Abnormal uterine bleeding, Woman, Medicine

NEW YORK, July 28, 2022 /PRNewswire/ -- AvoMD, a next-generation, application-based clinical decision support platform, is working with the American Academy of Family Physicians (AAFP) to transform algorithms developed by the AAFP journal American Family Physician (AFP) into actionable, instant guidance at the point-of-care.

Key Points: 
  • NEW YORK, July 28, 2022 /PRNewswire/ -- AvoMD, a next-generation, application-based clinical decision support platform, is working with the American Academy of Family Physicians (AAFP) to transform algorithms developed by the AAFP journal American Family Physician (AFP) into actionable, instant guidance at the point-of-care.
  • Family physicians are among the busiest of all providers, having 82 patient encounters per week on average.
  • The tool empowers family physicians to deliver the best possible care tailored to individual patient needs.
  • Today, family physicians provide more care for America's underserved and rural populations than any other medical specialty.

Exposure to 'Forever Chemicals' Costs U.S. Billions in Health Costs

Retrieved on: 
화요일, 7월 26, 2022
Linda, Diabetes, Hazard ratio, PFAS, World, Environment, United Nations Environment Programme, Philadelphia, MPH, Water, United States Environmental Protection Agency, Center, American Academy, Houghton Mifflin Harcourt, High society, United Nations, Population health, Pesticide, Pediatrics (journal), Woman, Electronics, Endometriosis, Infertility, Research, National, Hypothyroidism, Travel, MPP, Footprint, World Health Organization, Uterus, Obesity, New York University Grossman School of Medicine, Cancer, Hospital, Endocrine Society, Pediatrics, Einstein Medical Center Philadelphia, Plastic, Pneumonia, MD, Blood, Department, NYU, National Health and Nutrition Examination Survey, Kidney, Investor, Thyroid disease, Population, Hormone, NYU Langone Health, Health insurance, Pharmaceutical industry, Medicine, Doctor of Philosophy, Health

The substances are believed to disrupt the function of hormones, signaling compounds that influence many bodily processes.

Key Points: 
  • The substances are believed to disrupt the function of hormones, signaling compounds that influence many bodily processes.
  • Together, the diseases generate medical bills and reduce worker productivity across a lifetime to create the costs measured by the study, say the study authors.
  • Previous investigations have quantified the medical burden and financial costs of low birth weight due to PFAS exposure.
  • However, the new study, publishing online July 26 in the journal Exposure and Health, incorporates a much broader range of health consequences across the lifespan, says Kahn.